Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GELS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GELS
About GELS
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gelteq Limited Reports Clinical and Commercial Milestones for H1 2026
- Clinical Trial Progress: Gelteq has completed planning for its human clinical trial, expected to commence on July 1, 2026, advancing its pharmaceutical program toward an FDA regulatory pathway, marking a significant milestone in the biotechnology sector.
- Animal Health Program Launch: The company has initiated a veterinary clinical trial for an antiparasitic drug candidate, with a planned FDA application targeted for later in 2026, addressing a global animal health market exceeding $78 billion, showcasing substantial commercial potential.
- Strategic Financing Agreement: Gelteq signed a strategic debt financing agreement of up to $3.5 million with an institutional investor, with an initial funding of $1 million, aimed at supporting clinical program advancement and commercialization acceleration.
- East Asian Market Expansion: The company successfully manufactured a commercial product for a new customer in the East Asian region, validating its capabilities in formulation, manufacturing, and delivery at commercial scale, further solidifying its position in the rapidly growing pharmaceutical market.
See More
Gelteq Completes Successful Veterinary Palatability Trials
- Trial Success: Gelteq, in collaboration with Kemin, has successfully completed veterinary palatability trials, demonstrating strong canine acceptance across various flavors, validating the potential of Gelteq® technology in veterinary pharmaceuticals.
- Technology Validation: The trials confirmed Gelteq® technology's ability to effectively mask bitter flavors while enhancing palatability, providing crucial data to support the successful development of animal therapeutics.
- Strategic Partnership Opportunities: The results are expected to strengthen Gelteq's position in the veterinary therapeutics landscape and facilitate potential partnership discussions with pharmaceutical companies and animal health organizations.
- Broad Market Prospects: Gelteq's CEO stated that the successful trial outcomes not only broaden the range of active pharmaceutical ingredients that can be utilized but also enhance the company's competitiveness in the evolving animal health market.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
Gelteq Establishes Center of Excellence in Guangdong, China
- Regional Innovation Hub: Gelteq's establishment of a Center of Excellence in Guangdong, China, will serve as a strategic regional hub, enhancing integration with one of the world's fastest-growing pharmaceutical and biotechnology ecosystems, thereby strengthening the company's globally integrated development platform.
- Accelerated Product Development: The center is expected to support accelerated product development and commercialization timelines, expand formulation, testing, and product optimization capabilities, and increase the capacity to advance multiple development programs simultaneously, significantly improving operational efficiency.
- Market Participation Opportunities: According to PharmCube, cross-border out-licensing transactions originating from China are estimated at nearly $60 billion in deal value during Q1 2026, positioning Gelteq to participate more closely in the rapidly expanding biotechnology and pharmaceutical innovation market and seize lucrative commercial opportunities.
- Strategic Development Goals: CEO Nathan Givoni stated that the establishment of this center represents a significant milestone in expanding Gelteq's global development and commercial capabilities, aiming to drive long-term product pipeline development through enhanced operational scalability and accelerated product development.
See More
Gelteq Initiates First Clinical Trial for Veterinary Drug Candidate
- Clinical Trial Launch: Gelteq has announced the initiation of its first clinical trial for an antiparasitic drug candidate, marking a significant milestone as the company expands into the veterinary pharmaceutical sector, with plans to support an FDA application later in 2026.
- Technology Application Expansion: This clinical trial aims to validate the safety and efficacy of Gelteq® technology in the animal health sector, further solidifying its application potential in the veterinary market and positioning the company to capture opportunities in a rapidly growing market.
- Market Opportunities: The global animal health market is projected to exceed USD $78 billion by 2026, with antiparasitic treatments representing a significant segment driven by increasing pet ownership and ongoing demand for parasite prevention, which Gelteq plans to leverage for expanding its commercial prospects.
- Sufficient Funding: Gelteq's recent financing provides the company with adequate capital to execute its dual-track strategy of advancing long-term pharmaceutical projects while also driving near-term revenue growth through its nutraceutical portfolio, enhancing overall financial health.
See More
Gelteq Secures $3.5 Million Debt Financing for Growth
- Financing Amount: Gelteq Limited announced it has secured up to $3.5 million in debt financing, which includes $1 million at closing and an additional $2.5 million subject to shareholder approval expected in June.
- Clinical Trial Expansion: The proceeds will be utilized to expand clinical trial programs, support regulatory pathways for pharmaceutical products, and accelerate the commercialization of its nutraceutical products, thereby enhancing the company's competitive position in the market.
- No Repayment Pressure: The financing agreement stipulates no repayments for at least six months from closing, providing the company ample time to implement its commercialization strategy and drive revenue growth.
- Strategic Implications: This financing not only strengthens Gelteq's R&D capabilities but also positions the company favorably in the rapidly growing nutraceutical market, further propelling long-term growth.
See More
Gelteq Limited Reports Clinical and Commercial Milestones for H1 2026
- Clinical Trial Progress: Gelteq has completed planning for its human clinical trial, expected to commence on July 1, 2026, advancing its pharmaceutical program toward an FDA regulatory pathway, marking a significant milestone in the biotechnology sector.
- Animal Health Program Launch: The company has initiated a veterinary clinical trial for an antiparasitic drug candidate, with a planned FDA application targeted for later in 2026, addressing a global animal health market exceeding $78 billion, showcasing substantial commercial potential.
- Strategic Financing Agreement: Gelteq signed a strategic debt financing agreement of up to $3.5 million with an institutional investor, with an initial funding of $1 million, aimed at supporting clinical program advancement and commercialization acceleration.
- East Asian Market Expansion: The company successfully manufactured a commercial product for a new customer in the East Asian region, validating its capabilities in formulation, manufacturing, and delivery at commercial scale, further solidifying its position in the rapidly growing pharmaceutical market.
See More
Gelteq Completes Successful Veterinary Palatability Trials
- Trial Success: Gelteq, in collaboration with Kemin, has successfully completed veterinary palatability trials, demonstrating strong canine acceptance across various flavors, validating the potential of Gelteq® technology in veterinary pharmaceuticals.
- Technology Validation: The trials confirmed Gelteq® technology's ability to effectively mask bitter flavors while enhancing palatability, providing crucial data to support the successful development of animal therapeutics.
- Strategic Partnership Opportunities: The results are expected to strengthen Gelteq's position in the veterinary therapeutics landscape and facilitate potential partnership discussions with pharmaceutical companies and animal health organizations.
- Broad Market Prospects: Gelteq's CEO stated that the successful trial outcomes not only broaden the range of active pharmaceutical ingredients that can be utilized but also enhance the company's competitiveness in the evolving animal health market.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
Gelteq Establishes Center of Excellence in Guangdong, China
- Regional Innovation Hub: Gelteq's establishment of a Center of Excellence in Guangdong, China, will serve as a strategic regional hub, enhancing integration with one of the world's fastest-growing pharmaceutical and biotechnology ecosystems, thereby strengthening the company's globally integrated development platform.
- Accelerated Product Development: The center is expected to support accelerated product development and commercialization timelines, expand formulation, testing, and product optimization capabilities, and increase the capacity to advance multiple development programs simultaneously, significantly improving operational efficiency.
- Market Participation Opportunities: According to PharmCube, cross-border out-licensing transactions originating from China are estimated at nearly $60 billion in deal value during Q1 2026, positioning Gelteq to participate more closely in the rapidly expanding biotechnology and pharmaceutical innovation market and seize lucrative commercial opportunities.
- Strategic Development Goals: CEO Nathan Givoni stated that the establishment of this center represents a significant milestone in expanding Gelteq's global development and commercial capabilities, aiming to drive long-term product pipeline development through enhanced operational scalability and accelerated product development.
See More
Gelteq Initiates First Clinical Trial for Veterinary Drug Candidate
- Clinical Trial Launch: Gelteq has announced the initiation of its first clinical trial for an antiparasitic drug candidate, marking a significant milestone as the company expands into the veterinary pharmaceutical sector, with plans to support an FDA application later in 2026.
- Technology Application Expansion: This clinical trial aims to validate the safety and efficacy of Gelteq® technology in the animal health sector, further solidifying its application potential in the veterinary market and positioning the company to capture opportunities in a rapidly growing market.
- Market Opportunities: The global animal health market is projected to exceed USD $78 billion by 2026, with antiparasitic treatments representing a significant segment driven by increasing pet ownership and ongoing demand for parasite prevention, which Gelteq plans to leverage for expanding its commercial prospects.
- Sufficient Funding: Gelteq's recent financing provides the company with adequate capital to execute its dual-track strategy of advancing long-term pharmaceutical projects while also driving near-term revenue growth through its nutraceutical portfolio, enhancing overall financial health.
See More
Gelteq Secures $3.5 Million Debt Financing for Growth
- Financing Amount: Gelteq Limited announced it has secured up to $3.5 million in debt financing, which includes $1 million at closing and an additional $2.5 million subject to shareholder approval expected in June.
- Clinical Trial Expansion: The proceeds will be utilized to expand clinical trial programs, support regulatory pathways for pharmaceutical products, and accelerate the commercialization of its nutraceutical products, thereby enhancing the company's competitive position in the market.
- No Repayment Pressure: The financing agreement stipulates no repayments for at least six months from closing, providing the company ample time to implement its commercialization strategy and drive revenue growth.
- Strategic Implications: This financing not only strengthens Gelteq's R&D capabilities but also positions the company favorably in the rapidly growing nutraceutical market, further propelling long-term growth.
See More
